Detection of circulating tumor cells in high-risk endometrial cancer

Giorgio Bogani, Minetta C. Liu, Sean C. Dowdy, William A. Cliby, Sarah E. Kerr, Kimberly R. Kalli, Benjamin R. Kipp, Kevin C. Halling, Michael B. Campion, Andrea Mariani

Research output: Contribution to journalArticle

Abstract

Aim: To evaluate the presence of circulating tumor cells (CTCs) in patients with high-risk endometrial cancer (EC). Patients and Methods: We prospectively included 28 patients with a preoperative diagnosis of grade 3 EC undergoing surgery from June 2010 to December 2011. Their preoperative blood samples were tested for the presence of CTCs using an immunomagnetic and immunofluorescence assay technique. Results: Overall, 2 out of 28 patients (7%) were positive for CTCs. The presence of positive CTCs was significantly associated with myometrial invasion (MI) (33% vs. 0% for MI >50% vs. ≤50%; p=0.04) and lymph node positivity (40% vs. 0% for positive vs. negative nodes; p=0.03). Only patients with endometrioid histology had positive CTCs (29% in endometrioid vs. 0% in nonendometrioid; p=0.06). Conclusion: The presence of positive CTCs was associated with deep MI and lymph node positivity. The absence of CTCs in patients with type II histology suggests the need to find other markers in this subgroup of patients.

Original languageEnglish
Pages (from-to)683-687
Number of pages5
JournalAnticancer Research
Volume35
Issue number2
Publication statusPublished - Feb 1 2015

Keywords

  • Circulating tumor cells
  • Endometrial cancer
  • Hematogenous dissemination
  • Prognosis
  • Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Detection of circulating tumor cells in high-risk endometrial cancer'. Together they form a unique fingerprint.

  • Cite this

    Bogani, G., Liu, M. C., Dowdy, S. C., Cliby, W. A., Kerr, S. E., Kalli, K. R., Kipp, B. R., Halling, K. C., Campion, M. B., & Mariani, A. (2015). Detection of circulating tumor cells in high-risk endometrial cancer. Anticancer Research, 35(2), 683-687.